Market Overview

UPDATE: Benchmark Company Initiates Coverage on Varian Medical Systems with Buy Rating, $88 PT

Share:
Related VAR
Benzinga's Top Upgrades, Downgrades For September 7, 2017
Varian Rides on Oncology and Proton Therapy Businesses

In a report published Friday, Benchmark Company initiated coverage on Varian Medical Systems (NYSE: VAR) with a Buy rating and $88.00 price target.

Benchmark noted, “We are initiating coverage of Varian Medical Systems, Inc. (VAR) with a Buy rating and a 12-month price target of $88, or 20 times our fiscal 2014 EPS estimate of $4.42. Based on its historical range, we believe VAR should trade in a range of 15 to 20 times future earnings and, given its world-wide leadership in technology, its backlog, and installed base of customers, our target is based at the top of that range.”

Varian Medical Systems closed on Thursday at $67.74.

Latest Ratings for VAR

DateFirmActionFromTo
Sep 2017BTIG ResearchDowngradesBuyNeutral
May 2017Goldman SachsInitiates Coverage OnNeutral
May 2017BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for VAR
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Initiation Analyst Ratings

 

Related Articles (VAR)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...